Products

TREN SCHNELL
TREN SCHNELL
2019-07-30
ORAL-TURINABOL
ANAPOLON
2019-07-30
Show all

TRENBOLONE

Details
Potency200 mg / ml
Appearanceoil based solution
Packing1ml *10 clear glass ampoules*
IndicationsTRENBOLONE (trenbolone enanthate) is indicated in treatment of severe muscular dystrophy and severe unrelated muscular catabolism as well as acute growth failure.

* Supplied in a clear 1ml glass ampoules with breaking line and labeled box

* Contains ethyl oleate

Notes on temperatures the properties:

At cold storage temperatures the properties of this oil-based solution might temporarily change (e.g. higher viscosity, cloudiness). If stored at cold temperature, the product should be brought to room or body temperature before use. The solution for intramuscular injection is to be visually inspected prior to use and only clear solutions free from particles should be used.

Notes on handling the OPC (One-Point-Cut) ampoule:

There is a pre-scored mark beneath the coloured point on the ampoule eliminating the need to file the neck. Prior to opening, ensure that any solution in the upper part of the ampoule flows down to the lower part. Ensure that temperature of ampule is between 33-38 °C. Use both hands to open; while holding the lower part of the ampoule in one hand, use the other hand to break off the upper part of the ampoule in the direction away from the coloured point.

Storage
Store at room temperature, 15° – 30°C (59° – 86°F).
Avoid freezing and cool temperatures below 15°(59°F).

If freezing occurs and crystals are present, contact the manufacturer representative.

Description

Trenbolone, also known as trienolone or trienbolone, is a steroid used on livestock to increase muscle growth and appetite. To increase its effective half-life, trenbolone is administered as a prodrug as an ester conjugate such as trenbolone acetate, trenbolone enanthate, or trenbolone cyclohexylmethylcarbonate. Plasma lipases then cleave the ester group in the bloodstream leaving free trenbolone.

CAS number10161-33-8WeightAverage: 270.372
Monoisotopic: 270.161979948Chemical FormulaC18H22O2InChI KeyMEHHPFQKXOUFFV-OWSLCNJRSA-NInChI

InChI=1S/C18H22O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h8-10,15-17,20H,2-7H2,1H3/t15-,16+,17+,18+/m1/s1

IUPAC Name

(1S,3aS,3bS,11aS)-1-hydroxy-11a-methyl-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,11aH-cyclopenta[a]phenanthren-7-one

 

Medical uses

Trenbolone is useful such as the treatment of conditions like androgen deficiency, wasting syndromes and muscle atrophy, and certain types of anemia.

Acknowledgments

Trenbolone can stimulate the following most typical activities: acceleration of protein synthesis and maintenance of positive nitrogen balance, trenbolone greatly increases the level of the extremely anabolic hormone IGF-1 (insulin-like growth factor) within muscle tissue, increase the levels of IGF-1 in muscle over two fold, it also causes muscle satellite cells to be more sensitive to IGF-1 and other growth factors. The amount of DNA per muscle cell may also be significantly increased, increase the production of red blood cells responsible for transporting oxygen in the bloodstream. The more red blood cells are in blood, the better is oxygen saturation of organs, including muscles, which is very important for the development of muscular endurance. In addition, trenbolone promotes glycogen replenishment considerably improving recovery.  It also has the ability to significantly reduce the production of anti-anabolic (muscle destroying) glucocorticoid hormones, in particular cortisol. Trenbolone (a potent synthetic testosterone analogue that is not a substrate for 5-alpha reductase or for aromatase) induces myotrophic effects in skeletal muscle without causing prostate enlargement, which is in contrast to the known prostate enlarging effects of testosterone. These previous results suggest that the 5α-reduction of testosterone is not required for myotrophic action. We now report differential gene expression in response to testosterone versus trenbolone in the highly androgen-sensitive levator ani/bulbocavernosus (LABC) muscle complex of the adult rat after 6weeks of orchiectomy (ORX), using real time PCR. The ORX-induced expression of atrogenes (Muscle RING-finger protein-1 [MuRF1] and atrogin-1) was suppressed by both androgens, with trenbolone producing a greater suppression of atrogin-1 mRNA compared to testosterone. Both androgens elevated expression of anabolic genes (insulin-like growth factor-1 and mechano-growth factor) after ORX. ORX-induced increases in expression of glucocorticoid receptor (GR) mRNA were suppressed by trenbolone treatment, but not testosterone. In ORX animals, testosterone promoted WNT1-inducible-signaling pathway protein 2 (WISP-2) gene expression while trenbolone did not. Testosterone and trenbolone equally enhanced muscle regeneration as shown by increases in LABC mass and in protein expression of embryonic myosin by western blotting. In addition, testosterone increased WISP-2 protein levels. Together, these findings identify specific mechanisms by which testosterone and trenbolone may regulate skeletal muscle maintenance and growth.

Trenbolone Improves Cardiometabolic Risk Factors and Myocardial Tolerance to Ischemia-Reperfusion in Male Rats With Testosterone-Deficient Metabolic Syndrome. Trenbolone treatment elicits favorable changes in body composition (specifically, in the reduction of visceral adiposity), lipid profile, insulin sensitivity, and myocardial tolerance to ischemia reperfusion in Testosterone-deficient male rats with the MetS. In comparison with Trenbolone, the therapeutic effects of Testosterone were consistently less pronounced in these animals. Additionally, widespread replacement fibrosis in the myocardium and prostate hyperplasia were identified as consequences of Testosterone treatment and were markedly less pronounced in Trenbolone-treated animals. Neither the androgen-deficient state nor the treatment with Testosterone or Trenbolone affected the hepatic or renal activity in these animals. We propose that Testosterone replacement therapy may have contraindications in Testosterone-deficient males with obesity-related MetS, and that selective AR modulation with Trenbolone may elicit a preferable benefit to risk ratio in these populations

 

https://academic.oup.com/endo/article/157/1/368/2251856

https://www.ncbi.nlm.nih.gov/pubmed/24928725

Attention

Spectrum Pharma does not ship to countries, which classify these pharmaceuticals as special controlled or scheduled substances, including but not limited to the United States, Australia, Canada and Europe.

  • – We do not sell any products online.
  • – We do not sale to the public.
  • – We do not ship any products.
  • – We are not directly or indirectly associated with any websites that may engage in selling same or similar products.


Information contained within this website is not a prescription to use and is intended for information purposes only. Our products are made in Europe area and follow local laws accordingly, but FOR EXPORT ONLY. All manufacturing is in accordance with USP or BP Guidelines. Please Note: We are not an online store. We do not sell or ship to the USA, Europe, Australia or any other locations where prohibited. All information contained within this website or in any literature provided is not a prescription to use. Please seek the advise of a physician specializing in Andrology before use.